World Economic Forum: women’s health gets only 20% of R&D funding. We must seize this $1 trillion opportunity

May 18, 2026 - 09:33

A fresh analysis backed by the Gates Foundation and Wellcome Leap has spotlighted a glaring imbalance in medical research. According to the data, less than 3% of all clinical trials are designed specifically for women, while overall research and development funding directed at women's health accounts for only one-fifth of total investment. The World Economic Forum, which released the findings, is framing this gap not just as a health crisis but as a massive economic blind spot.

The report argues that closing the gender health gap could unlock a $1 trillion opportunity for the global economy. When women are underserved by medical science, they suffer longer with chronic conditions, face higher rates of misdiagnosis, and lose productive years of work. The WEF points out that conditions affecting women uniquely or disproportionately, such as endometriosis, menopause, and autoimmune diseases, remain drastically underfunded relative to their burden of disease.

Beyond the moral imperative, the math is straightforward: healthier women contribute more to the workforce, reduce healthcare system strain, and drive innovation. The call to action is for governments, private investors, and pharmaceutical companies to rebalance their portfolios. Seizing this opportunity means funding basic science, running inclusive trials, and treating women's health as a core pillar of economic strategy rather than a niche concern.